title: RNA blood levels of osteopontin splice variants are cancer markers.
abstract: OBJECTIVE
  Despite a sizeable and continuously growing literature on osteopontin and cancer the molecule has not yet found entry into clinical diagnostics. Our identification of spliced variants that are more specific for cancer than the full-length transcript has opened new possibilities for reaching this goal.
  
  
  METHODS
  Here we have developed a real-time RT-PCR blood test and evaluated it in a pilot study of breast, lung, pancreatic, gynecologic, and other cancers, compared to non-cancer controls.
  
  
  RESULTS
  Osteopontin-b was increased in lung cancers and pancreatic cancers. When applying a cutoff of 2 standard deviations above normal, elevation in osteopontin-b transcripts detected over 40% of lung cancers. Osteopontin-c was increased in gynecologic and pancreatic cancers. Elevation in osteopontin-c of 2 standard deviations above the normal mean value also detected a fraction of breast cancers and lung cancers, suggesting heterogeneity within those types of tumors. Specifically, breast carcinomas were associated with significantly higher levels of osteopontin-c mRNA in the blood than carcinomas in situ. In lung cancer patients, the osteopontin-c blood RNA levels had an increasing trend with tumor grade.
  
  
  CONCLUSIONS
  Osteopontin-b and -c in the blood are biomarkers for distinct cancers. Our investigations may have bearing on cancer screening and diagnosis.
authors.affiliation: University of Cincinnati Academic Health Center, College of Pharmacy, 3225 Eden Avenue, Cincinnati, OH 45267-0004 USA.
authors.forename: Franz
authors.initials: F
authors.lastname: Hartung
authors.forename: Georg F
authors.initials: GF
authors.lastname: Weber
keywords: Biomarker; Blood analysis; Breast cancer; Cancer progression; Lung cancer
references.citation: Br J Cancer. 2010 Sep 7;103(6):861-9
references.pmid: 20823889
references.citation: Cancer Genomics Proteomics. 2011 Nov-Dec;8(6):263-88
references.pmid: 22086896
references.citation: Biochem Biophys Res Commun. 1988 Nov 30;157(1):166-73
references.pmid: 3058125
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4771-6
references.pmid: 18779603
references.citation: Am J Surg. 2000 Dec;180(6):446-8; discussion 448-9
references.pmid: 11182395
references.citation: Mol Cancer Res. 2011 Mar;9(3):280-93
references.pmid: 21263033
references.citation: Anticancer Res. 1989 Sep-Oct;9(5):1291-9
references.pmid: 2686530
references.citation: Oncol Rep. 2011 Feb;25(2):433-41
references.pmid: 21165579
references.citation: Int J Cancer. 2000 Jan 20;89(1):8-13
references.pmid: 10719724
references.citation: Acta Oncol. 2007;46(2):221-9
references.pmid: 17453373
references.citation: Nucleic Acids Res. 2001 May 1;29(9):e45
references.pmid: 11328886
references.citation: Surgery. 2009 Aug;146(2):232-40
references.pmid: 19628079
references.citation: Oncogene. 2006 Apr 6;25(15):2192-202
references.pmid: 16288209
references.citation: Lung Cancer. 2007 Sep;57(3):373-80
references.pmid: 17513004
references.citation: Int J Cancer. 2008 Feb 15;122(4):889-97
references.pmid: 17960616
references.citation: Clin Cancer Res. 2001 Dec;7(12):4060-6
references.pmid: 11751502